What is it about?

123 French medical centers participated to the Personalized Reimbursement Model (PRM) program, involving 25,660 Breast Cancer patients (tracked since January 1st, 2011), and 5,070 Lung Cancer (tracked since January 1st, 2015). Are tracked Breast Cancer patients who were exposed at least to one of these drugs: trastuzumab, trastuzumab emtansin or pertuzumab. Are also tracked Lung Cancer patients who received at least one of these drugs: bevacizumab or atezolizumab. Main information collected were: patient characteristics, diagnostic, treatments, and involvement in clinical trial.

Featured Image

Why is it important?

1- A national representative registry: PRM covers 48% of Breast Cancer in-hospital therapeutic management in France. PRM covers 33% of Lung Cancer in-hospital therapeutic management in France. 2- Electronic Pharmacy Records data aggregation success Implementing such a platform requires building a data framework with a high level of standardization and interoperability in an environment fostering trust and confidence regarding data quality and data privacy. 3- Performance-Based Risk-Sharing Arrangement PRM program enabled setting the first Performance-Based Risk-Sharing Arrangement (PBRSA) based on real world data between the French Healthcare Products Pricing Committee (CEPS) and Roche for the first indication of atezolizumab cancer immunotherapy in second line advanced Non- Small Cell Lung Cancer (NSCLC) in February 2019.


Top experts of the field teamed-up to bring this ambitious program to life (almost 6 years between set-up and Performance-Based Risk-Sharing Arrangement). I hope this article will inspire public and private stakeholders as well as other countries to collaborate and build (inter)national real-world data programs willing to utilize real-world evidence to inform their healthcare decisions.

F Hoffmann-La Roche AG

Read the Original

This page is a summary of: Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France, PLoS ONE, April 2022, PLOS, DOI: 10.1371/journal.pone.0267242.
You can read the full text:

Open access logo



The following have contributed to this page